Diana Bernstein, Ph.D.

Diana Bernstein is a Principal at Northpond Ventures where she focuses on biotherapeutics investments. Diana is a Board Director at Code Biotherapeutics, Mestag Therapeutics, and OMass Therapeutics. Previously, Diana was a Senior Associate at MRL Ventures Fund, the corporate venture fund of Merck & Co. (NYSE: MRK), investing in early-stage therapeutics companies. Prior to that, she was an Associate at Flagship Pioneering, leading projects to conceive and build platform-based therapeutics companies. Diana also spent time in project management at Sigma-Tau Pharmaceuticals (now Leadiant Biosciences) and as an Associate at PricewaterhouseCoopers. She received her Ph.D. in pharmacology from the University of Pennsylvania, and a B.S. in finance and a B.S. in cell biology and molecular genetics from University of Maryland, College Park.